domingo, 12 de marzo de 2017

Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancers. - PubMed - NCBI

2017 Jan 11. pii: S0344-0338(16)30266-7. doi: 10.1016/j.prp.2017.01.004. [Epub ahead of print]

Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancers.

Kwon MJ1, Kim JW2, Jeon JY3, Nam ES4, Cho SJ4, Park HR5, Min SK5, Seo J5, Min KW6, Choe JY5, Lee HK5.

Author information

Abstract

Hepatocyte growth factor (HGF) and MET are candidates of targeted therapies for cancer patients. Although MET and HGF are commonly expressed in biliary tract cancers, their expression and gene copy number status and their association with KRAS mutations have not been investigated in pancreatobiliary-type ampullary adenocarcinomas (A-ACs), one of the aggressive periampullary cancers. MET and HGF expressions and MET copy number status were examined by performing immunohistochemistry (IHC) and silver in situ hybridization (SISH) in 62 surgically resected, paraffin-embedded tumors, respectively. High MET and HGF protein expressions were detected in 24 (38.7%) and 15 (24.2%) tumors. High MET expression was associated with KRAS mutation. However, there were no associations of high MET/HGF expression alone with other clinicopathological feature or survival. MET SISH positivity was detected in 19 tumors (30.6%), where 84.2% were due to high trisomy or polysomy and only 3 cases (15.8%) were MET gene amplification. The overall MET protein overexpression was well correlated with MET SISH positivity. The concurrent MET SISH positivity and KRAS mutation, not each alone, was an independent poor prognostic factor of disease-free survival only in pancreatobiliary subtype of A-ACs, but not in intestinal subtype. Concurrent MET SISH positivity and KRAS mutation may predict a high risk of recurrence in pancreatobiliary subtype of A-ACs, indicating those markers could be potent candidates for a new therapeutic target in this cancer type. MET IHC can be used as a reliable tool screening for MET copy number status in ampullary cancers.

KEYWORDS:

Adenocarcinoma; Ampulla of Vater; HGF; Immunohistochemistry; MET; Silver in situ hybridization

PMID:: 28214200
DOI:: 10.1016/j.prp.2017.01.004

From HuGE Literature Finder Database

This database contains published literature on genetic associations and other human genome epidemiology

Concurrent MET copy number gain and KRAS mutation is a poor prognostic factor in pancreatobiliary subtype ampullary cancers.
Pathology, research and practice 2017 Jan .
Kwon Mi Jung, Kim Jeong Won, Jeon Jang Yong, Nam Eun Sook, Cho Seong Jin, Park Hye-Rim, Min Soo Kee, Seo Jinwon, Min Kyueng-Whan, Choe Ji-Young, Lee Hye Kyu
A polymorphism (rs1042522) in TP53 gene is a risk factor for Down Syndrome in Sicilian mothers.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2016 Dec 1-3.
Salemi Michele, Barone Concetta, Salluzzo Maria Grazia, Giambirtone Mariaconcetta, Scillato Francesco, Galati Rando Rosanna, Romano Carmelo, Morale Maria Concetta, Ridolfo Federico, Romano Corra
ASXL1 mutations are frequent in de novo AML with trisomy 8 and confer an unfavorable prognosis.
Leukemia & lymphoma 2016 Oct 1-3.
Zong Xiangping, Yao Hong, Wen Lijun, Ma Liang, Wang Qinrong, Yang Zhiluo, Zhang Tongtong, Chen Suning, Depei
Detection of CALR Mutation in Clonal and Nonclonal Hematologic Diseases Using Fragment Analysis and Next-Generation Sequencing.
American journal of clinical pathology 2016 Oct 146 (4): 448-55.
Gardner Juli-Anne, Peterson Jason D, Turner Scott A, Soares Barbara L, Lancor Courtney R, Dos Santos Luciana L, Kaur Prabhjot, Ornstein Deborah L, Tsongalis Gregory J, de Abreu Francine
Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia.
Hematological oncology 2016 Sep .
Le Bris Yannick, Struski Stéphanie, Guièze Romain, Rouvellat Caroline, Prade Naïs, Troussard Xavier, Tournilhac Olivier, Béné Marie C, Delabesse Eric, Ysebaert Lo